Treatment of progressive supranuclear palsy and corticobasal degeneration
Identifieur interne : 003694 ( Main/Curation ); précédent : 003693; suivant : 003695Treatment of progressive supranuclear palsy and corticobasal degeneration
Auteurs : Anthony E. Lang [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Cerebral Cortex (pathology), Cholinesterase Inhibitors (therapeutic use), Corpus Striatum (pathology), Degeneration, Dopamine Agents (therapeutic use), Dopamine Agonists (therapeutic use), Dystonia, Dystonia (drug therapy), Dystonia (pathology), Globus Pallidus (pathology), Humans, Indans (therapeutic use), Levodopa (therapeutic use), Myoclonus, Nerve Degeneration (drug therapy), Nerve Degeneration (pathology), Nervous system diseases, Piperidines (therapeutic use), Substantia Nigra (pathology), Supranuclear Palsy, Progressive (drug therapy), Treatment, corticobasal degeneration, dopaminergic drugs, dystonia, myoclonus, progressive supranuclear palsy, tauopathy.
- MESH :
- chemical , therapeutic use : Amantadine, Cholinesterase Inhibitors, Dopamine Agents, Dopamine Agonists, Indans, Levodopa, Piperidines.
- drug therapy : Dystonia, Nerve Degeneration, Supranuclear Palsy, Progressive.
- pathology : Cerebral Cortex, Corpus Striatum, Dystonia, Globus Pallidus, Nerve Degeneration, Substantia Nigra.
- Humans.
Abstract
Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low. This finding probably relates to the widespread distribution of the pathological changes that account for the varied and complex spectrum of clinical manifestations. Dopaminergic drugs are regularly used for the parkinsonian features; however, these rarely result in more than modest benefit, and when better or sustained responses are obtained, as sometimes occurs in progressive supranuclear palsy, the clinical features are atypical and diagnosis is often delayed or not made in life. A variety of other treatments have been used in both disorders, sometimes directed at other specific features such as dystonia or myoclonus, and these treatments will be reviewed. Greater success in treating these disorders will require advances in our understanding of their cause(s) or the pathogenetic mechanisms underlying the neurodegenerative processes. The similarities in the molecular pathology of these four‐repeat tauopathies suggests that important advances in the management of one will have a definite impact on the treatment of the other. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20545
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001226
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001226
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002100
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F31
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002F31
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002F25
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001381
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001381
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001381
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004D77
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D74
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000F47
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C80
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005158
Links to Exploration step
ISTEX:34D5205CDF905C7B26D043384B2C0A8A70BB204ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:34D5205CDF905C7B26D043384B2C0A8A70BB204E</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20545</idno>
<idno type="url">https://api.istex.fr/document/34D5205CDF905C7B26D043384B2C0A8A70BB204E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001226</idno>
<idno type="wicri:Area/Istex/Curation">001226</idno>
<idno type="wicri:Area/Istex/Checkpoint">002100</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16092096</idno>
<idno type="wicri:Area/PubMed/Corpus">002F31</idno>
<idno type="wicri:Area/PubMed/Curation">002F31</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F25</idno>
<idno type="wicri:Area/Ncbi/Merge">001381</idno>
<idno type="wicri:Area/Ncbi/Curation">001381</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001381</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:Area/Main/Merge">004D77</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0457541</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D74</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F47</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C80</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:Area/Main/Merge">005158</idno>
<idno type="wicri:Area/Main/Curation">003694</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, Movement Disorders Clinic, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">S12</biblScope>
<biblScope unit="supplement">S12</biblScope>
<biblScope unit="page" from="S83">S83</biblScope>
<biblScope unit="page" to="S91">S91</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">34D5205CDF905C7B26D043384B2C0A8A70BB204E</idno>
<idno type="DOI">10.1002/mds.20545</idno>
<idno type="ArticleID">MDS20545</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term>
<term>Cerebral Cortex (pathology)</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Corpus Striatum (pathology)</term>
<term>Degeneration</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dystonia</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (pathology)</term>
<term>Globus Pallidus (pathology)</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Myoclonus</term>
<term>Nerve Degeneration (drug therapy)</term>
<term>Nerve Degeneration (pathology)</term>
<term>Nervous system diseases</term>
<term>Piperidines (therapeutic use)</term>
<term>Substantia Nigra (pathology)</term>
<term>Supranuclear Palsy, Progressive (drug therapy)</term>
<term>Treatment</term>
<term>corticobasal degeneration</term>
<term>dopaminergic drugs</term>
<term>dystonia</term>
<term>myoclonus</term>
<term>progressive supranuclear palsy</term>
<term>tauopathy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Cholinesterase Inhibitors</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Indans</term>
<term>Levodopa</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Nerve Degeneration</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Corpus Striatum</term>
<term>Dystonia</term>
<term>Globus Pallidus</term>
<term>Nerve Degeneration</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Dégénérescence</term>
<term>Myoclonie</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low. This finding probably relates to the widespread distribution of the pathological changes that account for the varied and complex spectrum of clinical manifestations. Dopaminergic drugs are regularly used for the parkinsonian features; however, these rarely result in more than modest benefit, and when better or sustained responses are obtained, as sometimes occurs in progressive supranuclear palsy, the clinical features are atypical and diagnosis is often delayed or not made in life. A variety of other treatments have been used in both disorders, sometimes directed at other specific features such as dystonia or myoclonus, and these treatments will be reviewed. Greater success in treating these disorders will require advances in our understanding of their cause(s) or the pathogenetic mechanisms underlying the neurodegenerative processes. The similarities in the molecular pathology of these four‐repeat tauopathies suggests that important advances in the management of one will have a definite impact on the treatment of the other. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2005:Lang A:treatment:of:progressive"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Hospital, Movement Disorders Clinic</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457541</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457541 INIST</idno>
<idno type="RBID">Pascal:05-0457541</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D74</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F47</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C80</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:Area/Main/Merge">005158</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Hospital, Movement Disorders Clinic</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Degeneration</term>
<term>Dystonia</term>
<term>Myoclonus</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dégénérescence</term>
<term>Dystonie</term>
<term>Myoclonie</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low. This finding probably relates to the widespread distribution of the pathological changes that account for the varied and complex spectrum of clinical manifestations. Dopaminergic drugs are regularly used for the parkinsonian features; however, these rarely result in more than modest benefit, and when better or sustained responses are obtained, as sometimes occurs in progressive supranuclear palsy, the clinical features are atypical and diagnosis is often delayed or not made in life. A variety of other treatments have been used in both disorders, sometimes directed at other specific features such as dystonia or myoclonus, and these treatments will be reviewed. Greater success in treating these disorders will require advances in our understanding of their cause(s) or the pathogenetic mechanisms underlying the neurodegenerative processes. The similarities in the molecular pathology of these four-repeat tauopathies suggests that important advances in the management of one will have a definite impact on the treatment of the other.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:34D5205CDF905C7B26D043384B2C0A8A70BB204E</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20545</idno>
<idno type="url">https://api.istex.fr/document/34D5205CDF905C7B26D043384B2C0A8A70BB204E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001226</idno>
<idno type="wicri:Area/Istex/Curation">001226</idno>
<idno type="wicri:Area/Istex/Checkpoint">002100</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16092096</idno>
<idno type="wicri:Area/PubMed/Corpus">002F31</idno>
<idno type="wicri:Area/PubMed/Curation">002F31</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F25</idno>
<idno type="wicri:Area/Ncbi/Merge">001381</idno>
<idno type="wicri:Area/Ncbi/Curation">001381</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001381</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lang A:treatment:of:progressive</idno>
<idno type="wicri:Area/Main/Merge">004D77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of progressive supranuclear palsy and corticobasal degeneration</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, Movement Disorders Clinic, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">S12</biblScope>
<biblScope unit="supplement">S12</biblScope>
<biblScope unit="page" from="S83">S83</biblScope>
<biblScope unit="page" to="S91">S91</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">34D5205CDF905C7B26D043384B2C0A8A70BB204E</idno>
<idno type="DOI">10.1002/mds.20545</idno>
<idno type="ArticleID">MDS20545</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term>
<term>Cerebral Cortex (pathology)</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Corpus Striatum (pathology)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (pathology)</term>
<term>Globus Pallidus (pathology)</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Nerve Degeneration (drug therapy)</term>
<term>Nerve Degeneration (pathology)</term>
<term>Piperidines (therapeutic use)</term>
<term>Substantia Nigra (pathology)</term>
<term>Supranuclear Palsy, Progressive (drug therapy)</term>
<term>corticobasal degeneration</term>
<term>dopaminergic drugs</term>
<term>dystonia</term>
<term>myoclonus</term>
<term>progressive supranuclear palsy</term>
<term>tauopathy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Cholinesterase Inhibitors</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Indans</term>
<term>Levodopa</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Nerve Degeneration</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Corpus Striatum</term>
<term>Dystonia</term>
<term>Globus Pallidus</term>
<term>Nerve Degeneration</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low. This finding probably relates to the widespread distribution of the pathological changes that account for the varied and complex spectrum of clinical manifestations. Dopaminergic drugs are regularly used for the parkinsonian features; however, these rarely result in more than modest benefit, and when better or sustained responses are obtained, as sometimes occurs in progressive supranuclear palsy, the clinical features are atypical and diagnosis is often delayed or not made in life. A variety of other treatments have been used in both disorders, sometimes directed at other specific features such as dystonia or myoclonus, and these treatments will be reviewed. Greater success in treating these disorders will require advances in our understanding of their cause(s) or the pathogenetic mechanisms underlying the neurodegenerative processes. The similarities in the molecular pathology of these four‐repeat tauopathies suggests that important advances in the management of one will have a definite impact on the treatment of the other. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:34D5205CDF905C7B26D043384B2C0A8A70BB204E |texte= Treatment of progressive supranuclear palsy and corticobasal degeneration }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |